International Stem Cell

International Stem Cell Corporation (ISCO) is advancing a novel regenerative medicine platform using human parthenogenetic stem cells (hpSCs) to develop immune-matched, off-the-shelf therapies. Its core mission is to address the major scalability and compatibility limitations of traditional allogeneic cell therapies by creating a bank of stem cell lines that could match a large percentage of the global population. The company's strategy is focused on translating its platform into clinical treatments for neurological, joint, and liver disorders where cell therapy has shown promise but is limited by cell supply. ISCO is led by a scientifically experienced management team and supported by a notable scientific advisory board.

Human parthenogenetic activation to create pluripotent stem cells (hpSCs) with a homozygous HLA profile, enabling the development of immune-matched, off-the-shelf cell therapies from a limited bank of cell lines.

ISCO competes with BlueRock Therapeutics, Aspen Neuroscience, and Mesoblast in regenerative medicine, differentiating through the inherent HLA homozygosity of its parthenogenetic stem cells. Its success depends on proving this offers a superior balance of immune coverage, scalability, and efficacy compared to iPSC-based or adult stem cell approaches.